Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Christina Lau, 14 Oct 2019

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

10 Mar 2017
The addition of pravastatin to standard chemotherapy does not improve outcomes in patients with small-cell lung cancer (SCLC), results of a study have shown.
Tristan Manalac, 03 Dec 2019
Incorporating basic tumour characteristics, such as hormone receptor status and tumour origin, improves the power of the cell-loss metric to predict response to treatment, according to a new study presented at the recently concluded 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).

Incomplete excision likely in poorly differentiated cSCCs

18 Jan 2020

Poorly differentiated cutaneous squamous cell carcinomas (cSCCs) are likely to be incompletely excised in peripheral and deep planes, despite adherence to the British Association of Dermatology-British Association of Plastic, Reconstructive and Aesthetic Surgery guidelines, reports a recent UK study.

Researchers enrolled 296 patients (69.3 percent male) who had had primary cSCCs excised between January 2017 and April 2018. Majority of the participants were >80 years of age (n=157; 53.0 percent). The malignancies were also most commonly found on high-risk sites, such as the face and scalp (n=206; 69.6 percent).

Almost half of the sample (48.0 percent) had moderately differentiated cSCCs, while 33.4 percent had well-differentiated lesions. Thirty-eight patients had poorly differentiated cSCC, corresponding to a 12.8-percent prevalence rate. The remaining patients either had well-to-moderately or moderately-to-poorly differentiated lesions.

Both moderately and poorly differentiated lesions were excised with wider margins than well differentiated cSCCs (6.4 and 5.6 vs 4.7 mm). Despite this, ordinal regression analysis found that poorly differentiated lesions were significantly more likely than their well differentiated counterparts to be excised with close or involved peripheral margins (odds ratio [OR], 45.02, 95 percent confidence interval [CI], 3.71–546.23; p=0.003).

Depth margins likewise varied with histological grade. Both moderately and poorly differentiated lesions were more often excised to deeper planes than well differentiated cSCCs. However, the risk of having close or involved deep margins remained significantly elevated in both cases relative to well differentiated lesions (moderate: OR, 5.10, 95 percent CI, 1.50–17.30; p=0.009; poor: OR, 11.94, 95 percent CI, 2.69–53.04; p=0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Christina Lau, 14 Oct 2019

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

10 Mar 2017
The addition of pravastatin to standard chemotherapy does not improve outcomes in patients with small-cell lung cancer (SCLC), results of a study have shown.
Tristan Manalac, 03 Dec 2019
Incorporating basic tumour characteristics, such as hormone receptor status and tumour origin, improves the power of the cell-loss metric to predict response to treatment, according to a new study presented at the recently concluded 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).